ClinicalTrials.gg
CompletedNCT05032196Updated Aug 12, 2025Results posted

Study of WVE-003 in Patients With Huntington's Disease

A Phase 1/2 interventional study of SAD: 30mg WVE-003 and SAD: 60mg WVE-003 in Huntington Disease, sponsored by Wave Life Sciences USA, Inc.. Completed at 23 sites in 10 countries. Open to participants aged 25 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by Wave Life Sciences USA, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
25 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Huntington Disease with a site in United Kingdom — 10 open to participants now, 15 under way, 3 of them phase 3. Huntington Disease · United Kingdom.

Enrollment
25th of 38
47 · median 92
Started
2021
with 2 others
Phase 1/2
8 of 51
1 open now
Registered
32nd of 51
by date
Lead sponsor
3 of 51
Wave Life Sciences USA, Inc.

Among the 51 studies in Huntington Disease with a site in United Kingdom, this one is the 25th largest by enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2021, is one of 8 in phase 1/2, and was the 32nd registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

10 of the 51 studies in Huntington Disease with a site in United Kingdom are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 25 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Huntington Disease with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of WVE-003 in adult patients with early-manifest HD who carry the targeted single nucleotide polymorphism (SNP) - SNP3.

03

Conditions studied

  • Huntington Disease

Browse trials for

04

Who can participate

Ages eligible
25 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Presence of the A variant of SNP3 on the same allele as the pathogenic CAG triplet expansion
  2. Ambulatory, male or female patients aged ≥25 to ≤60 years
  3. Clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score = 4
  4. UHDRS Total Functional Capacity Scores ≥9 and ≤13

Exclusion criteria

Exclusion Criteria:

  1. or received treatment for malignancy, other than treated basal cell or squamous cell carcinoma of the skin, within the previous 5 years
  2. Received any other study drug, including an oligonucleotide, within the past 1 year or 5 half-lives of the drug, whichever is longer, with the exception of the following:

    a. Received WVE-120101 or WVE-120102 within the last 3 months

  3. Implantable CNS device that may interfere with ability to administer study drug via lumbar puncture or undergo MRI scan
  4. Inability to undergo brain MRI (with or without sedation)
  5. Bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or unsuccessful lumbar puncture
  6. Previously received tominersen
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
47 participants (actual)

Study arms

  • Placebo comparator
    SAD: Pooled Placebo

    Placebo

    Drug: SAD: Pooled Placebo

  • Experimental
    SAD: 30mg WVE-003

    Single Ascending Dose - 30mg WVE-003

    Drug: SAD: 30mg WVE-003

  • Experimental
    SAD: 60mg WVE-003

    Single Ascending Dose - 60mg WVE-003

    Drug: SAD: 60mg WVE-003

  • Experimental
    SAD: 90mg WVE-003

    Single Ascending Dose - 90mg WVE-003

    Drug: SAD: 90mg WVE-003

  • Placebo comparator
    MD: Placebo

    Placebo

    Drug: MD: Placebo

  • Experimental
    MD: 30mg WVE-003

    Multiple Dose - 30mg WVE-003

    Drug: MD: 30mg WVE-003

Interventions

  • DrugSAD: 30mg WVE-003

    Single ascending dose of 30mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)

  • DrugSAD: 60mg WVE-003

    Single ascending dose of 60mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)

  • DrugSAD: 90mg WVE-003

    Single ascending dose of 90mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)

  • DrugSAD: Pooled Placebo

    Single dose of placebo

  • DrugMD: 30mg WVE-003

    Three doses of 30mg WVE-003 Q8WK an allele-selective stereopure, antisense oligonucleotide (ASO)

  • DrugMD: Placebo

    Three doses of placebo Q8WK

06

What researchers measure

Primary outcomes

  1. Safety: Proportion of Patients With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug

    The primary outcome for this study was safety and is reported as the proportion of patients with TEAEs related to study drug.

    Time frame: Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2)

Secondary outcomes

  1. Pharmacokinetics of WVE-003 in Plasma

    Parameter analyzed: AUC0-6 = area under the concentration-time curve from time 0 to 6 hrs

    Time frame: Day 1 (single ascending dose Period 1); Day 1 and Day 113 (multi dose Period 2)

  2. Pharmacokinetics of WVE-003 in Plasma

    Parameter analyzed: Cmax = maximum observed concentration.

    Time frame: Day 1 (single ascending dose Period 1); Day 1 and Day 113 (multi dose Period 2)

  3. Concentration of WVE-003 in Cerebrospinal Fluid (CSF)

    WVE-003 concentration in cerebrospinal fluid (CSF) is reported in ng/mL.

    Time frame: 28 days post-dose during Period 1 (P1:Day29); 28 days post last dose during Period 2 (P2: Day141)

07

Results

Posted Aug 12, 2025

Participant flow

Period 1 (Single Ascending Dose)
Participant flow — Period 1 (Single Ascending Dose)
MilestoneSAD: Pooled PlaceboSAD: 30mg WVE-003*SAD: 60mg WVE-003*SAD: 90mg WVE-003MD: PlaceboMD: 30mg WVE-003
Started161211800
Completed161111700
Not completed010100
Withdrew: Withdrawal by subject010000
Withdrew: Adverse event000100
Period 2 (Multidose)
Participant flow — Period 2 (Multidose)
MilestoneSAD: Pooled PlaceboSAD: 30mg WVE-003*SAD: 60mg WVE-003*SAD: 90mg WVE-003MD: PlaceboMD: 30mg WVE-003
Started0000716
Treated0000716
Completed0000616
Not completed000010
Withdrew: Physician decision000010

Outcome measures

PrimarySafety: Proportion of Patients With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug

The primary outcome for this study was safety and is reported as the proportion of patients with TEAEs related to study drug.

Time frame:
Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2)
Reported as:
Count of participants · Participants
Safety: Proportion of Patients With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug
ParticipantsSAD: Pooled PlaceboSAD: 30mg WVE-003SAD: 60mg WVE-003SAD: 90mg WVE-003MD: PlaceboMD: 30mg WVE-003
Safety: Proportion of Patients With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug213308
SecondaryPharmacokinetics of WVE-003 in Plasma

Parameter analyzed: AUC0-6 = area under the concentration-time curve from time 0 to 6 hrs

Time frame:
Day 1 (single ascending dose Period 1); Day 1 and Day 113 (multi dose Period 2)
Reported as:
Mean · AUC 0-6 (hr*ng/mL)
Pharmacokinetics of WVE-003 in Plasma
AUC 0-6 (hr*ng/mL)SAD: 30mg WVE-003SAD: 60mg WVE-003SAD: 90mg WVE-003MD: 30mg WVE-003
D1: AUC 0-6 (hr*ng/mL)1000 ± 7022310 ± 30903890 ± 2900822 ± 409
D113: AUC 0-6 (hr*ng/mL)———698 ± 432
SecondaryPharmacokinetics of WVE-003 in Plasma

Parameter analyzed: Cmax = maximum observed concentration.

Time frame:
Day 1 (single ascending dose Period 1); Day 1 and Day 113 (multi dose Period 2)
Reported as:
Mean · Cmax (ng/mL)
Pharmacokinetics of WVE-003 in Plasma
Cmax (ng/mL)SAD: 30mg WVE-003SAD: 60mg WVE-003SAD: 90mg WVE-003MD: 30mg WVE-003
D1: Cmax (ng/mL)240 ± 168601 ± 7741061 ± 942186 ± 106
D113: Cmax (ng/mL)———157 ± 97.3
SecondaryConcentration of WVE-003 in Cerebrospinal Fluid (CSF)

WVE-003 concentration in cerebrospinal fluid (CSF) is reported in ng/mL.

Time frame:
28 days post-dose during Period 1 (P1:Day29); 28 days post last dose during Period 2 (P2: Day141)
Reported as:
Mean · ng/mL
Concentration of WVE-003 in Cerebrospinal Fluid (CSF)
ng/mLSAD: 30mg WVE-003SAD: 60mg WVE-003SAD: 90mg WVE-003MD: 30mg WVE-003
Concentration of WVE-003 in Cerebrospinal Fluid (CSF)3.6405 ± 1.61335.5346 ± 2.84027.0983 ± 3.13354.2903 ± 1.9722

Adverse events

Collected over Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SAD: Pooled Placebo0/16 (0%)1/16 (6.3%)13/16 (81.3%)
SAD: 30mg WVE-0030/13 (0%)0/13 (0%)9/13 (69.2%)
SAD: 60mg WVE-0030/10 (0%)1/10 (10%)8/10 (80%)
SAD: 90mg WVE-0030/8 (0%)0/8 (0%)8/8 (100%)
MD: Placebo0/7 (0%)0/7 (0%)7/7 (100%)
MD: 30mg WVE-0030/16 (0%)0/16 (0%)13/16 (81.3%)
Most frequent serious events
Most frequent serious events
EventSAD: Pooled PlaceboSAD: 30mg WVE-003SAD: 60mg WVE-003SAD: 90mg WVE-003MD: PlaceboMD: 30mg WVE-003
AtaxiaNervous system disorders0/160/131/100/80/70/16
Post lumbar puncture syndromeInjury, poisoning and procedural complications1/160/130/100/80/70/16
Most frequent other events
Showing 10 of 86
Most frequent other events
EventSAD: Pooled PlaceboSAD: 30mg WVE-003SAD: 60mg WVE-003SAD: 90mg WVE-003MD: PlaceboMD: 30mg WVE-003
HeadacheNervous system disorders6/164/132/104/83/74/16
FallInjury, poisoning and procedural complications1/160/131/103/82/72/16
Back painMusculoskeletal and connective tissue disorders1/163/132/101/82/70/16
Post lumbar puncture syndromeInjury, poisoning and procedural complications2/161/131/102/81/70/16
Procedural painInjury, poisoning and procedural complications0/161/130/102/81/70/16
CSF white blood cell count increasedInvestigations0/161/130/102/80/72/16
CSF protein increasedInvestigations0/162/131/102/80/71/16
NauseaGastrointestinal disorders0/161/130/102/80/70/16
FatigueGeneral disorders2/162/130/101/81/72/16
Pain in extremityMusculoskeletal and connective tissue disorders0/162/130/100/80/70/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)SAD: Pooled PlaceboSAD: 30mg WVE-003SAD: 60mg WVE-003SAD: 90mg WVE-003MD: PlaceboMD: 30mg WVE-003Total
Period 145.5 ± 7.447.8 ± 9.243.9 ± 8.649.6 ± 5.3——46.5 ± 7.9
Period 2————45.6 ± 8.347.8 ± 8.347.1 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)SAD: Pooled PlaceboSAD: 30mg WVE-003SAD: 60mg WVE-003SAD: 90mg WVE-003MD: PlaceboMD: 30mg WVE-003Total
Period 1 — Female6633——18
Period 1 — Male10775——29
Period 2 — Female————257
Period 2 — Male————51116
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SAD: Pooled PlaceboSAD: 30mg WVE-003SAD: 60mg WVE-003SAD: 90mg WVE-003MD: PlaceboMD: 30mg WVE-003Total
Period 1 — Hispanic or Latino1000——1
Period 1 — Not Hispanic or Latino1513108——46
Period 1 — Unknown or Not Reported0000——0
Period 2 — Hispanic or Latino————101
Period 2 — Not Hispanic or Latino————61622
Period 2 — Unknown or Not Reported————000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SAD: Pooled PlaceboSAD: 30mg WVE-003SAD: 60mg WVE-003SAD: 90mg WVE-003MD: PlaceboMD: 30mg WVE-003Total
Period 1 — American Indian or Alaska Native0000——0
Period 1 — Asian0000——0
Period 1 — Native Hawaiian or Other Pacific Islander0000——0
Period 1 — Black or African American0000——0
Period 1 — White1613108——47
Period 1 — More than one race0000——0
Period 1 — Unknown or Not Reported0000——0
Period 2 — American Indian or Alaska Native————000
Period 2 — Asian————000
Period 2 — Native Hawaiian or Other Pacific Islander————000
Period 2 — Black or African American————71623
Period 2 — White————000
Period 2 — More than one race————000
Period 2 — Unknown or Not Reported————000
08

Study locations

23 sites
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Monash Health
    Clayton, Victoria 3168, Australia
  • Royal Melbourne Hospital
    Melbourne, Victoria 3050, Australia
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2G3, Canada
  • The Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • Centre Hospitalier de l-Universite de Montreal
    Montreal, Quebec H2X019, Canada
  • Rigshospitalet
    Copenhagen, 2100, Denmark
  • Hopital Henri Mondor - Hospital
    Créteil, 94010, France
  • Institut du Cerveau et de la Moelle Epiniere
    Paris, 75646, France
  • Katholisches Klinikum Bochum gGmbH
    Bochum, 44791, Germany
  • George-Huntington-Institut GmbH
    Münster, 48149, Germany
  • kbo-Isar-Amper-Klinikum Taufkirchen (Vils)
    Taufkirchen, 84416, Germany
  • Centro Ricerche Cliniche Di Verona
    Verona, Italy
  • Leiden University Medical Center
    Leiden, 2333 ZA, Netherlands
  • Maastricht University Medical Center
    Maastricht, 6229 HX, Netherlands
  • Szpital Sw. Wojciecha
    Gdansk, 80-462, Poland
  • Instytut Psychiatrii I Neurologii
    Warsaw, 02-957, Poland
  • Hospital de la Sanata Creu i Sant Pau
    Barcelona, 08041, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • Royal Devon and Exeter Hospital NHS Trust
    Exeter, Devon EX2 5DW, United Kingdom
  • Royal Hospital for Children, Pharmacy Aseptic Unit
    Glasgow, Glasgow City G51 4TF, United Kingdom
  • Cardiff University, Schools of Medicine and Biosciences
    Cardiff, Wales CF14 4XW, United Kingdom
  • Royal Liverpool University Hospital
    Liverpool, L7 8XP, United Kingdom
09

References and documents

Publications

  • Iwamoto N, Liu Y, Frank-Kamenetsky M, Maguire A, Tseng WC, Taborn K, Kothari N, Akhtar A, Bowman K, Shelke JD, Lamattina A, Hu XS, Jang HG, Kandasamy P, Liu F, Longo K, Looby R, Meena, Metterville J, Pan Q, Purcell-Estabrook E, Shimizu M, Prakasha PS, Standley S, Upadhyay H, Yang H, Yin Y, Zhao A, Francis C, Byrne M, Dale E, Verdine GL, Vargeese C. Preclinical evaluation of stereopure antisense oligonucleotides for allele-selective lowering of mutant HTT. Mol Ther Nucleic Acids. 2024 Jun 11;35(3):102246. doi: 10.1016/j.omtn.2024.102246. eCollection 2024 Sep 10. PubMed 39027419 ↗
  • Estevez-Fraga C, Tabrizi SJ, Wild EJ. Huntington's Disease Clinical Trials Corner: November 2022. J Huntingtons Dis. 2022;11(4):351-367. doi: 10.3233/JHD-229006. PubMed 36463457 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in May 2024, 32 months.

Results were first posted in Aug 2025, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2021
First posted
Sep 2, 2021
StartActual
Sep 6, 2021
Primary completionActual
May 24, 2024
CompletionActual
May 24, 2024
Results first posted
Aug 12, 2025
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05032196
Lead sponsor
Wave Life Sciences USA, Inc.
Responsible party
Sponsor
First posted
Sep 2, 2021
Start date
Sep 6, 2021
Primary completion
May 24, 2024
Completion
May 24, 2024
Results posted
Aug 12, 2025
Last update
Aug 12, 2025

Study contacts

Medical Director, MD
study director · Wave Life Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion